Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
BioSpace
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results "another derisking step" for the company's immunol
pharminent
March 30, 2026 (Last updated: March 30, 2026)
BioSpace
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunol
